This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release...
Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc....
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics...
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics...
Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,...
RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2)...
Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a...
Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE / October...
- Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy manufacturing...